Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Endeavour drug-eluting coronary stent system, which incorporates components developed by Abbott, Medtronic, Biocompatibles, and ScinoPharm, has been approved for marketing in Europe for the use during heart operations for coronary artery disease.
Subscribe to our email newsletter
Stents are used to keep arteries open during heart surgery. The Endeavour stent is known as a drug-eluting stent, which is coated with a drug that helps to prevent the re-clogging of arteries after the procedure.
The Endeavor stent combines Abbott’s patented drug Zotarolimus, Medtronic’s Driver Coronary Stent platform, and Biocompatibles PC Polymer into a drug-eluting stent system.
The Zotarolimus manufacturing process has been co-developed by Abbott and ScinoPharm, and ScinoPharm will continue to supply the drug substance for the Endeavor stent.
Drug-eluting stents have been shown to be superior to traditional bare-metal stents and can reduce the rate of repeat procedures due to re-clogging of arteries in patients with coronary disease.
The worldwide market for drug-eluting stents is approximately $5.5 billion, and is expected to grow at rapid pace. The size of the market outside of the US, excluding Japan, is between $ 1 billion and $1.5 billion.